Close menu

December 16th, 2021 | 11:42 CET

Formycon, CoinAnalyst, Aixtron - Buy the dip

  • crypto
Photo credits:

As an investor, who would not wish to buy stocks after a major setback at their lowest point and then go straight back to the top with them? The "buy the dip" strategy is mainly heard from self-appointed gurus from the crypto scene. But beware. Although major setbacks have recently emerged as lucrative buying opportunities in the highly volatile segment, Bitcoin & Co. are threatened with another slide to an even lower level.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: FORMYCON AG | DE000A1EWVY8 , CoinAnalyst Corp. | CA19260U1084 , AIXTRON SE NA O.N. | DE000A0WMPJ6

Table of contents:

    The asset class of the future

    From a technical perspective, at least another drop into the correction range around USD 35,000 is possible for Bitcoin in the short term. The chart picture was too damaged for that after the sell-off at the beginning of the month. In the long term, Bitcoin is considered the inflation protection of the future, also due to its limitation of a maximum of 21 million units. In the long term, another positive is that even the savings bank, which is considered old-fashioned, wants to allow its customers to trade digital currencies such as Bitcoin and Ethereum. According to the plans, Sparkasse customers would be able to buy cryptocurrencies directly through their current accounts. An advantage over crypto-only exchanges, where new customers must first identify themselves.

    Battered crypto companies

    The rapid but painful correction of the digital reserve currency from USD 69,275 to the current level of around USD 47,000 has seen crypto-related stocks take an extreme beating. MicroStrategy, the Company with the highest holdings in the world, already sank 30%. Smaller companies also lost double-digit value, so the imagination for the future and the chance for a more significant rebound are more than given in the fluctuating world. One example is the young, highly innovative company CoinAnalyst, which celebrated its stock market debut in Frankfurt with highs around EUR 0.20. Although quite successful steps have been reported in recent weeks, the current share price is EUR 0.095, and the stock market value is still a manageable EUR 8.13 million.

    The Canadian Big Data-based Company developed an artificial intelligence-based analytics platform that provides customers with access to a personalized dashboard that collects real-time data from the cryptocurrency market, such as coins, tokens and NFTs, from over 300 sources. It analyzes and evaluates them using Cogia AG's AI technology, which has been successful for years. In addition to the products "Insights" and "Crypto Market Letter", which is to appear globally in the future, the focus is primarily on the segment "Copy Trading". After the product's launch, which makes it possible to profit from trading experts and the AI-supported trading strategy, an average return of around 60% p.a. could be achieved. Based on the recent successes, the management plans to significantly increase capacity here.

    In addition to the launch of a mobile app planned for the first quarter of 2022, the non-fungible tokens segment is also to be increased. For the next few years, CoinAnalyst's management sees tremendous growth ahead. After revenues amounted to CAD 0.9 million this year, CAD 17.09 million is already planned for 2023.

    50% in one week

    It is not only the crypto market that is currently experiencing high volatility. Investors in vaccine manufacturers such as BioNTech, Moderna and CureVac are also changing the color of their faces more often than not due to the rapidly changing price picture. At Formycon, a leading and independent developer of high-quality biopharmaceutical follow-on products, so-called biosimilars, it has become quiet. After a brilliant start to the year, the share was rippling along, with prices above EUR 75. However, at the beginning of December, the share marked a low for the year at EUR 42.50.

    Two weeks later, the share price stands at EUR 60. The Martinsried-based Company announced a far-reaching cooperation for marketing the biosimilar FYB201, which offers further potential for the future. bioeq, licensee and exclusive holder of the worldwide marketing rights for the drug, had concluded an exclusive partnership with MS Pharma for the commercialization of FYB201 in the Middle East and North Africa.

    Distribution agreements for FYB201 are already in place for the US market and Europe, among others. "Upon successful approval of FYB201, Formycon will participate in the commercialization revenues in all territories," the Company said.

    Positive signs

    At the equipment manufacturer for the production of compound semiconductors and nanomaterials, Aixtron AG, an end to the correction is not yet apparent. The broad support area at EUR 16 should provide compelling support; otherwise, the price is threatened with further trouble and a slide towards EUR 15.

    Meanwhile, Morgan Stanley sent positive signals and initiated stock coverage with an "Equal Weight" rating and a price target of EUR 19. The analysts see the beginning of a multi-year growth cycle at Aixtron, driven by the topic of energy efficiency.

    The crypto market is in a correction. Although the long-term outlook remains extremely positive, a further sell-off should not be ruled out. CoinAnalyst is positioning itself in the Big Data analytics space and has its finger on the pulse with its platform. Caution is still advised for Aixtron.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by André Will-Laudien on March 11th, 2024 | 07:00 CET

    Bitcoin USD 70,000 - High-tech and artificial intelligence - a perennial favorite! Nvidia, Defense Metals, AMD and Super Micro Computer

    • Mining
    • RareEarths
    • hightech
    • AI
    • crypto

    It happened over the weekend: USD 70,000 - and no end in sight for Bitcoin? A never-ending rally seems to be taking its course after the cryptocurrency turned upwards at USD 25,000 last September. Will the upswing continue unabated? Due to the upcoming halving in April, this could continue for a few more weeks, with the crypto following growing daily. Suppliers in the high-tech sector are riding the same wave: fast computers, graphics cards, big data and artificial intelligence. Almost infinite growth is expected behind these megatrends. However, valuations are already very advanced. Where are the opportunities for newcomers now?


    Commented by Juliane Zielonka on March 1st, 2024 | 17:05 CET

    Cardiol Therapeutics, Bayer, Coinbase - Which share will generate profits in the long term?

    • Biotechnology
    • Pharma
    • crypto

    The world of pharmaceuticals and life sciences is characterized by precisely documented studies in clinical research. If an active ingredient makes it to approval, there is the potential for a blockbuster worth billions. Cardiol Therapeutics has an active ingredient in the second phase of clinical research for the treatment of heart disease in people under 35 years of age. This active ingredient can also restore the quality of life of 26 million people worldwide who suffer from heart failure. Bayer continues to clean up the unresolved issues left behind by the former CEO. Did the weedkiller RoundUp® from the Monsanto deal possibly lead to improper treatment due to a lack of consumer protection information? The five-figure lawsuits still pending against Roundup are dampening the share's profit prospects. The situation is currently quite different in the cryptocurrency market. Bitcoin is outperforming everyone, and the Coinbase share is benefiting from it. Which investment generates profits in the long term?


    Commented by Juliane Zielonka on February 29th, 2024 | 08:15 CET

    Defense Metals, Coinbase, Volkswagen: Critical metals for pioneering technologies

    • Mining
    • RareEarths
    • crypto
    • AI
    • Electromobility

    The demand for critical metals is increasing rapidly worldwide. From growing digitalization to the increased use of cryptocurrencies and AI, from advances in medical technology to electromobility and defense technology - all these areas rely on these critical raw materials. Defense Metals Corporation is an experienced explorer in British Columbia whose Wicheeda project is designed to provide these critical metals. Forward-thinking companies like the crypto exchange Coinbase serve many users who use rare earth metals to power their hard drives for crypto mining. Volkswagen also requires this raw material because car consumers in China have very different needs when it comes to vehicle software than those in the European market. A new CEO for the subsidiary and software company CARIAD knows exactly what needs to be done...